Simoa Grant Application

 
Off

Simoa Grant Application

Infectious Disease

Quanterix announces the Simoa Success Grant Program in support of investigators based in the United States who are studying critical topics at the intersection of laboratory and clinical research in Infectious Diseases and Immunology to introduce them to the benefits of Simoa assays for protein biomarker analysis.

The grant application submission period closed at 5 p.m. EDT on June 19, 2020. Candidates will be notified by July 3, 2020 if their application has been selected for a Quanterix Simoa Success award.

The grant application submission period closed on June 19, 2020 at 5:00 pm EDT.

Decision of the judges is final. Terms and conditions are subject to change without notice. Void where prohibited by law.


GRANT APPLICATION 1

-One proposal will be awarded a placement of a Quanterix SP-X® Instrument, Simoa® Microplate Washer, and Simoa® Microplate Shaker, plus all necessary assay kits and consumables to run the proposed study. Awardee will be trained by a Quanterix Field Application Scientist and supported through completion of the study. Should the awardee commit to additional projects utilizing Simoa® assay kits, the instrument placement will be permanent.

-Four proposals will be awarded free of charge sample analysis at Quanterix’ in-house, state-of-the-art CLIA certified Simoa® Accelerator Laboratory to complete the proposed study.

Applicants are encouraged to present an experimental plan for sample testing utilizing current Simoa assays to measure specific analyte levels. Preferred projects will address a basic or pre-clinical question aimed at demonstrating the use of specific protein biomarkers in diagnosis, prognosis, or treatment efficacy studies for diseases engaging the immune system. Up to 130 samples may be submitted for analysis with one assay kit, or up to 65 samples may be submitted for analysis with two assay kits. Appendix A lists the assay kits available for this grant.
 

DOWNLOAD THE APPLICATION
Rules and Regulations


GRANT APPLICATION 2

-Two proposals will be awarded free of charge novel assay prototyping and sample analysis demonstrating proof of concept for use of the assay to achieve specific research goals. Awardee will provide antibodies, antigen, and samples to Quanterix. Work will be completed at Quanterix headquarters, and all details of assay design will be shared with the awardee to enable future work based on the study.
 

Applicants are encouraged to present a plan for development of a novel Simoa assay utilizing the Quanterix SP-X platform and “Homebrew” assay kit. SP-X homebrew assays follow a sandwich ELISA format and require two target-specific antibodies, recognizing different epitopes. Assay development will also require a positive control sample, such as recombinant target protein, that can be diluted to generate a calibration curve. Proposals improving assay performance with a proven set of antibodies and calibrator from an existing ELISA that requires additional sensitivity will be considered less risky than those involving de novo use of reagent combinations. Preferred projects will address a need for high-sensitivity/specificity protein detection supporting diagnosis, prognosis, or treatment efficacy/kinetics/safety studies for diseases engaging the immune system. Analysis of up to 60 unique samples to show utility of the novel assay for a specific application may be included as part of the proposal.
 


Validated by more than 650 peer-reviewed publications, Quanterix is recognized throughout the industry as a world leader in biomarker detection. Operating at a sensitivity 1000 times greater than conventional ELISA platforms, Simoa has the proven ability to see and quantify biomarkers at concentrations previously undetectable. This unprecedented sensitivity has empowered researchers to study disease in new ways, allowing for earlier detection, improved understanding and monitoring of disease pathology, and a more accurate assessment of experimental therapeutics. Today, researchers around the world are actively deploying this technology to combat COVID-19 by leveraging Simoa® technology to unlock critical insights into the immune response through its robust, multiplexed assays for measuring cytokines, chemokines and antibodies.

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more